The impact of aspirin, statins and ACE-inhibitors on the presentation of colorectal neoplasia in a colorectal cancer screening programme

British Journal of Cancer

Volumn 109, Issue 1, 2013, Pages 249-256

  Mansouri, D ^a   McMillan, D C ^a   Roxburgh, C S D ^a   Crighton, E M ^b   Horgan, P G ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b GARTNAVEL ROYAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER RISK; CANCER SCREENING; COLONOSCOPY; COLORECTAL CANCER; COLORECTAL TUMOR; DRUG EFFECT; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OCCULT BLOOD TEST; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CHEMOPREVENTION; COLONOSCOPY; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MASS SCREENING; MIDDLE AGED; OCCULT BLOOD; PROSPECTIVE STUDIES; RISK;

EID: 84880311881     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.292     Document Type: Article

References (42)

1. Atkin WS, Saunders BP (2002) Surveillance guidelines after removal of colorectal adenomatous polyps. Gut 51(Suppl 5): V6-V9.
2. Bardou M, Barkun A, Martel M (2010) Effect of statin therapy on colorectal cancer. Gut 59: 1572-1585.
3. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeown- Eyssen G, Summers RW, Rothstein R, Burke CA, Snover DC, Church TR, Allen JI, Beach M, Beck GJ, Bond JH, Byers T, Greenberg ER, Mandel JS, Marcon N, Mott LA, Pearson L, Saibil F, van Stolk RU (2003) A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348: 891-899.
4. Benamouzig R, Deyra J, Martin A, Girard B, Jullian E, Piednoir B, Couturier D, Coste T, Little J, Chaussade S (2003) Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 125: 328-336.
5. Brenner H, Tao S, Haug U (2010) Low-dose aspirin use and performance of immunochemical fecal occult blood tests. JAMA 304: 2513-2520.
6. Burn J, Bishop DT, Chapman PD, Elliott F, Bertario L, Dunlop MG, Eccles D, Ellis A, Evans DG, Fodde R, Maher ER, Möslein G, Vasen HF, Coaker J, Phillips RK, Bu?low S, Mathers JC (2011a) A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. Cancer Prev Res (Phila) 4: 655-665.
7. Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S, Eccles D, Evans DG, Maher ER, Bertario L, Bisgaard ML, Dunlop MG, Ho JW, Hodgson SV, Lindblom A, Lubinski J, Morrison PJ, Murday V, Ramesar R, Side L, Scott RJ, Thomas HJ, Vasen HF, Barker G, Crawford G, Elliott F, Movahedi M, Pylvanainen K, Wijnen JT, Fodde R, Lynch HT, Mathers JC, Bishop DT (2011b) Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 378: 2081-2087.
8. Cancer Research UK. Available at http://info.cancerresearchuk.org/ cancerstats/(Accessed January 2013).
9. Chan AT, Arber N, Burn J, Chia WK, Elwood P, Hull MA, Logan RF, Rothwell PM, Schror K, Baron JA (2012) Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev Res (Phila) 5: 164-178.
10. Clarke P, Jack F, Carey FA, Steele RJ (2006) Medications with anticoagulant properties increase the likelihood of a negative colonoscopy in faecal occult blood test population screening. Colorectal Dis 8: 389-392.
11. Cole BF, Logan RF, Halabi S, Benamouzig R, Sandler RS, Grainge MJ, Chaussade S, Baron JA (2009) Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst 101: 256-266.
12. Flossmann E, Rothwell PM (2007) Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 369: 1603-1613.
13. Fraser CG, Digby J, McDonald PJ, Strachan JA, Carey FA, Steele RJ (2012) Experience with a two-tier reflex gFOBT/FIT strategy in a national bowel screening programme. J Med Screen 19: 8-13.
14. Gauthaman K, Fong CY, Bongso A (2009) Statins, stem cells, and cancer. J Cell Biochem 106: 975-983.
15. Guittet L, Bouvier V, Mariotte N, Vallee JP, Arsene D, Boutreux S, Tichet J, Launoy G (2007) Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population. Gut 56: 210-214.
16. Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, James PD, Mangham CM (1996) Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 348: 1472-1477.
17. Hol L, Wilschut JA, van Ballegooijen M, van Vuuren AJ, van der Valk H, Reijerink JC, van der Togt AC, Kuipers EJ, Habbema JD, van Leerdam ME (2009) Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. Br J Cancer 100: 1103-1110.
18. Jacobs RJ, Kodach LL, Hardwick JC (2011) The potential of statins for individualized colorectal cancer chemoprevention. Curr Drug Targets 12: 1903-1908.
19. Kedika R, Patel M, Pena Sahdala HN, Mahgoub A, Cipher D, Siddiqui AA (2011) Long-term use of angiotensin converting enzyme inhibitors is associated with decreased incidence of advanced adenomatous colon polyps. J Clin Gastroenterol 45: e12-e16.
20. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O (1996) Randomised study of screening for colorectal cancer with faecal-occultblood test. Lancet 348: 1467-1471.
21. Lee CS, McNamara D, O'Morain CA (2012) Aspirin as a chemoprevention agent for Colorectal cancer. Curr Drug Metab 13: 1313-1322.
22. Lee TJ, Hull MA, Rajasekhar PT, Clifford GM, Ritchie M, James P, McNally RJ, Rutter MD, Rees CJ (2012) Aspirin users attending for NHS bowel cancer screening have less colorectal neoplasia: chemoprevention or false-positive faecal occult blood testing? Digestion 85: 278-281.
23. Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL, Meredith PA, Murray LS, Reid JL, Robertson JW (1998) Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 352: 179-184.
24. Levi Z, Rozen P, Hazazi R, Vilkin A, Waked A, Maoz E, Birkenfeld S, Lieberman N, Klang S, Niv Y (2009) Sensitivity, but not specificity, of a quantitative immunochemical fecal occult blood test for neoplasia is slightly increased by the use of low-dose aspirin, NSAIDs, and anticoagulants. Am J Gastroenterol 104: 933-938.
25. Logan RF, Patnick J, Nickerson C, Coleman L, Rutter MD, von Wagner C (2012) Outcomes of the Bowel Cancer Screening Programme (BCSP) in England after the first 1 million tests. Gut 61: 1439-1446.
26. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, Ederer F (1993) Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 328: 1365-1371.
27. Mansouri D, McMillan DC, Grant Y, Crighton EM, Horgan PG (2013) The impact of age, sex and socioeconomic deprivation on outcomes in a colorectal cancer screening programme. PLoS One. Article accepted but not yet published.
28. Parra-Blanco A, Gimeno-Garća AZ, Quintero E, Nicola's D, Moreno SG, Jiménez A, Herna'ndez-Guerra M, Carrillo-Palau M, Eishi Y, Lo'pez- Bastida J (2010) Diagnostic accuracy of immunochemical versus guaiac faecal occult blood tests for colorectal cancer screening. J Gastroenterol 45: 703-712.
29. Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS, Low M, Greenson JK, Rennert G (2005) Statins and the risk of colorectal cancer. N Engl J Med 352: 2184-2192.
30. Proctor MJ, Talwar D, Balmar SM, O'Reilly DS, Foulis AK, Horgan PG, Morrison DS, McMillan DC (2010) The relationship between the presence and site of cancer, an inflammation-based prognostic score and biochemical parameters. Initial results of the Glasgow Inflammation Outcome Study. Br J Cancer 103: 870-876.
31. RockenC,Neumann K, Carl-McGrath S, Lage H, EbertMP, Dierkes J, JacobiCA, Kalmuk S, Neuhaus P, Neumann U (2007) The gene polymorphism of the angiotensin I-converting enzyme correlates with tumor size and patient survival in colorectal cancer patients. Neoplasia 9: 716-722.
32. Rodgers A, Patel A, Berwanger O, Bots M, Grimm R, Grobbee DE, Jackson R, Neal B, Neaton J, Poulter N, rafter N, Raju PK, Reddy S, Thom S, Vander Hoorn S, Webster R (2011) An international randomised placebocontrolled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk. PLoS One 6: e19857.
33. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW (2011) Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377: 31-41.
34. Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP, Meade TW (2010) Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376: 1741-1750.
35. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, Steinbach G, Schilsky R (2003) A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348: 883-890.
36. Sawhney MS, McDougall H, Nelson DB, Bond JH (2010) Fecal occult blood test in patients on low-dose aspirin, warfarin, clopidogrel, or non-steroidal anti-inflammatory drugs. Dig Dis Sci 55: 1637-1642.
37. Simon MS, Rosenberg CA, Rodabough RJ, Greenland P, Ockene I, Roy HK, Lane DS, Cauley JA, Khandekar J (2012) Prospective analysis of association between use of statins or other lipid-lowering agents and colorectal cancer risk. Ann Epidemiol 22: 17-27.
38. Steele RJ, McClements P, Watling C, Libby G, Weller D, Brewster DH, Black R, Carey FA, Fraser CG (2012) Interval cancers in a FOBT-based colorectal cancer population screening programme: implications for stage, gender and tumour site. Gut 61: 576-581.
39. Steele RJ, McClements PL, Libby G, Black R, Morton C, Birrell J, Mowat NA, Wilson JA, Kenicer M, Carey FA, Fraser CG (2009) Results from the first three rounds of the Scottish demonstration pilot of FOBT screening for colorectal cancer. Gut 58: 530-535.
40. Thun MJ, Namboodiri MM, Heath Jr. CW (1991) Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325: 1593-1596.
41. Wald NJ, Law MR (2003) A strategy to reduce cardiovascular disease by more than 80%. BMJ 326: 1419.
42. Zhou P, Cheng SW, Yang R, Wang B, Liu J (2012) Combination chemoprevention: future direction of colorectal cancer prevention. Eur J Cancer Prev 21: 231-240.